DON'T BUY

Clearly the leader. Everyone loves the Blackwell chip, and people pay a lot for it because there's no competitor. Grew revenues over 100% last 2 years; estimated at 50% this year. Tariff impact unknown. Risk is competition. Once we conclude the data centre buildout cycle, what then?

His firm owns AVGO as a proxy for the chip buildout.

HOLD

A volume business. Competitive advantage is not huge. Has done a great job. Don't be in any rush to get rid of it. Slow and steady.

HOLD
Down over 40%.

Very mature company. Probably very little square footage growth, so it's driven by same-store sales. Tariffs may also be an overhang. If no recession, could be a good time to buy.

BUY

So early in its growth phase. Square footage growth about 10-15% for next 5 years, and add that to same-store sales growth of ~5-6%. Under-penetrated in US.

BUY

Very narrow trading range over last 5 years. Bought KSU 2-3 years ago, yet still in the trading range. Headwind from trade issues. Its network should be fantastic once the trade deals are settled. Pulled back guidance for the year to low double-digit EPS growth. Longer term, should see high single-digit revenue growth.

The trade deals will get done. Goods still need to be shipped. He's positive on it.

BUY

Stock's down due to headwinds from macro economic concerns. Very well run, operations are spotless. Still runway for growth. Great chance to buy a quality company that's been hit.

COMMENT
Investing strategy in these uncertain times.

People will change their stripes as they get affected by different things. Current US president is blowing everything up from defunding research to challenging universities. 

His firm hasn't changed its approach. They look at everything from a bottom-up perspective. They have target prices on all stocks in a concentrated portfolio of 32-33 names. They also have target position sizes; if a stock drops, the team debates whether to buy it up to a full position. The macro is changing; but their method remains consistent, and that's served them well through current and past crises.

Upcoming mid-term elections plus lawsuits challenging tariffs should work in investors' favour. We have to hope that rules will fall into place and we can all move forward. 

TOP PICK

Historical bastion of consistency. Last quarter it became inconsistent, with a 12% guidance down on EPS because utilization rates went up (they were unable, for some reason, to calculate this accurately). Just a small improvement in these metrics will boost the stock. 20 years of excellent execution, so this hiccup is a great time to buy. Yield is 2.2%.

(Analysts’ price target is $536.65)
TOP PICK

Consulting on new technology rollouts globally for small, medium, and large businesses. Companies are going to need a lot of help implementing generative AI processes. This name is in the sweet spot for that revenue. Companies have to do this or be left behind. Yield is 1.9%.

(Analysts’ price target is $354.04)
TOP PICK

Behemoth and benchmark in luxury goods. Stock's been weak as consumers have pulled back globally, especially in China and US. Historically over all these cycles, their brands have performed very well. ROIC is very high, and can be sustained even through weak times. Very cheap at 17x PE. Growth is probably 0% this year, but once tariffs come through it will be bullish for the global luxury market. 

With so many brands under one banner, very flexible in terms of allocating capital and marketing support to one brand or another. (Price target in euros.) Yield is 2.6%.

(Analysts’ price target is $609.84)
COMMENT

Headlines will have a minimal impact, because it takes YEARS to negotiate a trade deal. Trump will reduce tariffs on China to 80%--still high. And America dealing with 10% tariffs: that's still a big deal because our economy was still slowing. Don't buy false comfort ahead of the trade talks. Near term, we're okay, but he expects a recession ahead.

DON'T BUY

Loves it. Cutting edge and a leader in the defence space. But the valuation is too high (192x forward PE). He's been watching it a long time. He missed this completely.

PARTIAL SELL

He sold part of this. In Q1, the FDA approved a record low number of drugs, and Vertex has some important trials. Was nervous in a macro standpoint, but company fundamentals and valuation were reasonable. He hopes for a bounce.

DON'T BUY

Has been a problem child for a while and not worth the headache; there are better retailers. TGT faces a weaker consumer.

RISKY

It's a trade. He bought Bitcoin below $90,000. Trump has strongly supported cryptos, so this still has momentum. It could return to $80K, but position this as a speculative asset in your portfolio. Others see value in it that he does not. The current move can continue to new highs.